Hongying Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongying Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Chunling Li
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
29 shared publications - Fangmin Li
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
29 shared publications - Huiwen Luan
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
29 shared publications - Jiashen Zhang
Department of Biochemistry and Molecular Biology, School of Life Sciences, Shandong Agricultural University, Tai'an, Shandong, China
29 shared publications - Ting Wang
Department of Pathology, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, China
29 shared publications - Xinyu Zhao
Zhongshan School of Medicine, Sun Yat-sen University Shenzhen Campus, Sun Yat-Sen University, Shenzhen, Guangdong, 518107, China
29 shared publications
Latest Publications
- Open Access
- 14 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e012889
Tumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape
Background: IGSF9, immunoglobulin superfamily member 9, has been reported to inhibit T cell proliferation and activation, thereby promoting tumor immune escape. Tumor-associated macrophages (TAMs), the most abundant tumor-infiltrating immune cells, play a crucial role in forming the immunosuppressive tumor microenvironment. We find that IGSF9 strongly binds to TAMs, however, how it affects TAMs function remains unreported. Methods: The spatial transcriptomics dataset (GSE189487) was analyzed to clarify the relationship among IGSF9, senescent TAMs, and T cells. RNA-seq revealed differentially expressed genes. Flow cytometry was employed to assess the binding of IGSF9-ECD proteins to macrophages. Macrophage-educated by IGSF9 were co-cultured with T cells, and the phagocytosis was observed. Membrane-system yeast two-hybrid screening, GST pull-down, and co-IP were used to identify the binding partner of IGSF9. Cellular senescence markers and the senescence-associated secretory phenotype (SASP) were assessed by flow cytometry and immunofluorescence. LL/2-control or LL/2- Igsf9 cells were injected into C57BL/6, NSG, and monocytes-depleted C57BL/6 mice. Similarly, MC38- OVA -control or MC38-OVA-Igsf9 cells were inoculated into OT-II mice. Finally, anti-IGSF9 and its LALA-PG-mutant variant were administered to C57BL/6 mice to monitor tumor growth and SASP expression. Results: The spatial transcriptomics dataset (GSE189487) revealed that the level of IGSF9 in tumor cells was positively correlated with the senescence of TAMs, and RNA-seq revealed the differentially expressed genes which were related to senescence. Macrophage educated by IGSF9 exhibited distinct senescence phenotypes and immunosuppressive features, and IGSF9 bound to TMUB1 to activate the IL-6/STAT3 signal pathway to trigger the above phenotype. In vivo data showed that IGSF9 could induce TAM senescence, leading to inhibition of T cell activity and formation of an immunosuppressive microenvironment, then promoting tumor immune escape. Treatment with anti-IGSF9, including the LALAPG-mutant variant that reduces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, mitigated TAM senescence and immunosuppression, activated T cells, and suppressed tumor growth. Conclusions: TMUB1 as a binding protein of IGSF9 is first discovered, and TAMs educated by IGSF9 exhibit senescent and suppressive phenotype to orchestrate an inhibitory tumor microenvironment, which can be reversed by anti-IGSF9 to suppress tumor progression.
- 14 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e012889
Open AccessTumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape
Background: IGSF9, immunoglobulin superfamily member 9, has been reported to inhibit T cell proliferation and activation, thereby promoting tumor immune escape. Tumor-associated macrophages (TAMs), the most abundant tumor-infiltrating immune cells, play a crucial role in forming the immunosuppressive tumor microenvironment. We find that IGSF9 strongly binds to TAMs, however, how it affects TAMs function remains unreported. Methods: The spatial transcriptomics dataset (GSE189487) was analyzed to clarify the relationship among IGSF9, senescent TAMs, and T cells. RNA-seq revealed differentially expressed genes. Flow cytometry was employed to assess the binding of IGSF9-ECD proteins to macrophages. Macrophage-educated by IGSF9 were co-cultured with T cells, and the phagocytosis was observed. Membrane-system yeast two-hybrid screening, GST pull-down, and co-IP were used to identify the binding partner of IGSF9. Cellular senescence markers and the senescence-associated secretory phenotype (SASP) were assessed by flow cytometry and immunofluorescence. LL/2-control or LL/2- Igsf9 cells were injected into C57BL/6, NSG, and monocytes-depleted C57BL/6 mice. Similarly, MC38- OVA -control or MC38-OVA-Igsf9 cells were inoculated into OT-II mice. Finally, anti-IGSF9 and its LALA-PG-mutant variant were administered to C57BL/6 mice to monitor tumor growth and SASP expression. Results: The spatial transcriptomics dataset (GSE189487) revealed that the level of IGSF9 in tumor cells was positively correlated with the senescence of TAMs, and RNA-seq revealed the differentially expressed genes which were related to senescence. Macrophage educated by IGSF9 exhibited distinct senescence phenotypes and immunosuppressive features, and IGSF9 bound to TMUB1 to activate the IL-6/STAT3 signal pathway to trigger the above phenotype. In vivo data showed that IGSF9 could induce TAM senescence, leading to inhibition of T cell activity and formation of an immunosuppressive microenvironment, then promoting tumor immune escape. Treatment with anti-IGSF9, including the LALAPG-mutant variant that reduces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, mitigated TAM senescence and immunosuppression, activated T cells, and suppressed tumor growth. Conclusions: TMUB1 as a binding protein of IGSF9 is first discovered, and TAMs educated by IGSF9 exhibit senescent and suppressive phenotype to orchestrate an inhibitory tumor microenvironment, which can be reversed by anti-IGSF9 to suppress tumor progression.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
THP-1-igsf9-WT not -igsf9-KO cells inhibited T cell proliferation in vitro.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
THP-1-igsf9-WT not -igsf9-KO cells inhibited T cell proliferation in vitro.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 reversed the inhibition of T cells mediated by IGSF9-ECD.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 reversed the inhibition of T cells mediated by IGSF9-ECD.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in normal tissue array.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in normal tissue array.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in tumor tissue arrays by immunohistochemistry.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in tumor tissue arrays by immunohistochemistry.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Supplementary material and methods and Supplementary tables
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Supplementary material and methods and Supplementary tables
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 regained the activation of T cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 regained the activation of T cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Mouse IGSF9 was detected before and after MC38 implantation.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Mouse IGSF9 was detected before and after MC38 implantation.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 itself did not affect tumor cell proliferation.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 itself did not affect tumor cell proliferation.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Human IGSF9 was detected in myeloid cells of peripheral blood from healthy donors and tumor patients.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Human IGSF9 was detected in myeloid cells of peripheral blood from healthy donors and tumor patients.